Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medication Adherence | 118 | 2024 | 2189 | 13.900 |
Why?
|
Anti-HIV Agents | 139 | 2024 | 4571 | 12.250 |
Why?
|
HIV Infections | 242 | 2024 | 17575 | 11.580 |
Why?
|
Uganda | 142 | 2024 | 1351 | 6.630 |
Why?
|
Anti-Retroviral Agents | 46 | 2023 | 1794 | 5.460 |
Why?
|
Latent Tuberculosis | 6 | 2024 | 224 | 3.000 |
Why?
|
Tuberculosis | 20 | 2024 | 2029 | 2.940 |
Why?
|
Reminder Systems | 13 | 2024 | 387 | 2.860 |
Why?
|
South Africa | 34 | 2024 | 1871 | 2.370 |
Why?
|
Sexually Transmitted Diseases | 8 | 2024 | 666 | 2.330 |
Why?
|
Antiretroviral Therapy, Highly Active | 23 | 2023 | 1903 | 2.310 |
Why?
|
Sexual Partners | 32 | 2024 | 806 | 2.250 |
Why?
|
Kenya | 32 | 2024 | 757 | 2.090 |
Why?
|
Rural Population | 33 | 2020 | 2318 | 1.890 |
Why?
|
Qualitative Research | 29 | 2024 | 3131 | 1.830 |
Why?
|
Viral Load | 31 | 2024 | 3398 | 1.820 |
Why?
|
Patient Compliance | 19 | 2020 | 2693 | 1.790 |
Why?
|
HIV Seropositivity | 20 | 2022 | 962 | 1.610 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2023 | 2202 | 1.520 |
Why?
|
Social Support | 14 | 2022 | 2190 | 1.500 |
Why?
|
Social Stigma | 17 | 2022 | 785 | 1.500 |
Why?
|
Truth Disclosure | 6 | 2021 | 433 | 1.360 |
Why?
|
HIV Seronegativity | 10 | 2020 | 210 | 1.340 |
Why?
|
Adenine | 14 | 2024 | 993 | 1.260 |
Why?
|
Patient Acceptance of Health Care | 11 | 2024 | 3230 | 1.220 |
Why?
|
HIV | 12 | 2023 | 1596 | 1.210 |
Why?
|
Telemedicine | 12 | 2024 | 3107 | 1.210 |
Why?
|
Counseling | 11 | 2024 | 1553 | 1.180 |
Why?
|
Disclosure | 8 | 2022 | 754 | 1.170 |
Why?
|
Family Characteristics | 14 | 2021 | 1003 | 1.140 |
Why?
|
Wireless Technology | 3 | 2017 | 99 | 1.140 |
Why?
|
Feasibility Studies | 10 | 2024 | 5311 | 1.130 |
Why?
|
Adult | 176 | 2024 | 223622 | 1.120 |
Why?
|
Motivation | 7 | 2024 | 2029 | 1.120 |
Why?
|
Caregivers | 9 | 2023 | 2303 | 1.120 |
Why?
|
Female | 227 | 2024 | 397050 | 1.110 |
Why?
|
Humans | 304 | 2024 | 768298 | 1.080 |
Why?
|
Drug Monitoring | 7 | 2020 | 964 | 1.070 |
Why?
|
Hair | 5 | 2020 | 507 | 1.070 |
Why?
|
Cardiotocography | 2 | 2017 | 31 | 1.030 |
Why?
|
HIV-1 | 29 | 2024 | 6963 | 1.030 |
Why?
|
Health Services Accessibility | 14 | 2024 | 5511 | 1.000 |
Why?
|
Sexual Behavior | 16 | 2024 | 2200 | 1.000 |
Why?
|
Glycerophospholipids | 3 | 2021 | 39 | 0.990 |
Why?
|
Young Adult | 78 | 2024 | 60048 | 0.980 |
Why?
|
Monitoring, Ambulatory | 3 | 2020 | 357 | 0.970 |
Why?
|
Pregnancy Complications, Infectious | 12 | 2024 | 2185 | 0.870 |
Why?
|
Chemoprevention | 6 | 2024 | 326 | 0.870 |
Why?
|
Oral Health | 2 | 2020 | 493 | 0.870 |
Why?
|
Lamivudine | 2 | 2024 | 367 | 0.860 |
Why?
|
Male | 169 | 2024 | 364870 | 0.860 |
Why?
|
Unsafe Sex | 3 | 2021 | 239 | 0.820 |
Why?
|
RNA, Viral | 8 | 2017 | 2866 | 0.790 |
Why?
|
Disease Transmission, Infectious | 7 | 2024 | 562 | 0.790 |
Why?
|
Homosexuality, Male | 9 | 2022 | 1345 | 0.780 |
Why?
|
Adolescent | 61 | 2024 | 89182 | 0.760 |
Why?
|
Interviews as Topic | 16 | 2024 | 2740 | 0.760 |
Why?
|
Focus Groups | 5 | 2024 | 1453 | 0.700 |
Why?
|
Administration, Oral | 13 | 2024 | 4043 | 0.690 |
Why?
|
Self Care | 4 | 2019 | 797 | 0.670 |
Why?
|
Vital Signs | 2 | 2021 | 144 | 0.640 |
Why?
|
Monitoring, Physiologic | 4 | 2021 | 1795 | 0.640 |
Why?
|
Electronics | 4 | 2024 | 317 | 0.640 |
Why?
|
Insecticide-Treated Bednets | 1 | 2019 | 70 | 0.630 |
Why?
|
Peer Group | 1 | 2024 | 698 | 0.630 |
Why?
|
Health Knowledge, Attitudes, Practice | 12 | 2024 | 4047 | 0.610 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2018 | 102 | 0.610 |
Why?
|
Pilot Projects | 15 | 2024 | 8730 | 0.590 |
Why?
|
Pregnant Women | 2 | 2019 | 577 | 0.590 |
Why?
|
Dental Health Services | 1 | 2017 | 48 | 0.580 |
Why?
|
Nevirapine | 2 | 2018 | 273 | 0.580 |
Why?
|
CD4 Lymphocyte Count | 20 | 2020 | 2596 | 0.580 |
Why?
|
Pregnancy | 43 | 2024 | 30198 | 0.570 |
Why?
|
Deoxycytidine | 11 | 2015 | 887 | 0.570 |
Why?
|
Postpartum Hemorrhage | 1 | 2021 | 273 | 0.560 |
Why?
|
Depression | 13 | 2020 | 8241 | 0.560 |
Why?
|
Patient Preference | 3 | 2021 | 947 | 0.550 |
Why?
|
Safe Sex | 7 | 2024 | 144 | 0.540 |
Why?
|
Contact Tracing | 5 | 2023 | 275 | 0.530 |
Why?
|
Asymptomatic Diseases | 1 | 2019 | 590 | 0.500 |
Why?
|
Maternal Health Services | 1 | 2021 | 471 | 0.490 |
Why?
|
Alcohol Drinking | 6 | 2023 | 4049 | 0.490 |
Why?
|
Remote Sensing Technology | 1 | 2016 | 92 | 0.490 |
Why?
|
Fertilization | 4 | 2024 | 198 | 0.480 |
Why?
|
Condoms | 7 | 2024 | 338 | 0.470 |
Why?
|
Postpartum Period | 10 | 2023 | 1197 | 0.470 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 3921 | 0.450 |
Why?
|
Rural Health Services | 2 | 2017 | 393 | 0.450 |
Why?
|
Child | 33 | 2024 | 80894 | 0.450 |
Why?
|
Professional-Patient Relations | 1 | 2019 | 726 | 0.440 |
Why?
|
Tuberculin Test | 3 | 2022 | 205 | 0.440 |
Why?
|
Gonorrhea | 3 | 2023 | 355 | 0.430 |
Why?
|
Delivery of Health Care | 7 | 2022 | 5375 | 0.430 |
Why?
|
Africa | 5 | 2021 | 726 | 0.430 |
Why?
|
Deception | 1 | 2014 | 100 | 0.430 |
Why?
|
Confidentiality | 3 | 2018 | 606 | 0.430 |
Why?
|
Contraception Behavior | 4 | 2020 | 187 | 0.420 |
Why?
|
Mass Screening | 7 | 2020 | 5451 | 0.420 |
Why?
|
Cesarean Section | 2 | 2021 | 1417 | 0.410 |
Why?
|
Developing Countries | 6 | 2022 | 2903 | 0.410 |
Why?
|
Self Report | 4 | 2019 | 3766 | 0.410 |
Why?
|
Oxazines | 2 | 2024 | 357 | 0.400 |
Why?
|
Mycobacterium tuberculosis | 2 | 2022 | 1931 | 0.400 |
Why?
|
Patient Care | 1 | 2017 | 629 | 0.390 |
Why?
|
Viremia | 5 | 2021 | 725 | 0.380 |
Why?
|
Infectious Disease Transmission, Vertical | 5 | 2021 | 1360 | 0.380 |
Why?
|
Prevalence | 19 | 2023 | 15868 | 0.380 |
Why?
|
Africa, Eastern | 5 | 2019 | 76 | 0.370 |
Why?
|
Telemetry | 1 | 2012 | 200 | 0.370 |
Why?
|
Middle Aged | 61 | 2024 | 223463 | 0.370 |
Why?
|
Resilience, Psychological | 1 | 2019 | 804 | 0.360 |
Why?
|
Prospective Studies | 41 | 2023 | 54921 | 0.360 |
Why?
|
Health Behavior | 2 | 2021 | 2647 | 0.350 |
Why?
|
Intention | 3 | 2020 | 348 | 0.350 |
Why?
|
Problem Solving | 1 | 2013 | 443 | 0.350 |
Why?
|
Kynurenine | 3 | 2017 | 142 | 0.350 |
Why?
|
HIV Integrase Inhibitors | 2 | 2022 | 165 | 0.340 |
Why?
|
Cohort Studies | 37 | 2024 | 41791 | 0.340 |
Why?
|
Longitudinal Studies | 17 | 2023 | 14783 | 0.340 |
Why?
|
Malaria | 1 | 2019 | 1241 | 0.330 |
Why?
|
Cross-Sectional Studies | 21 | 2022 | 26373 | 0.330 |
Why?
|
Patient Satisfaction | 3 | 2017 | 3485 | 0.330 |
Why?
|
Chlamydia Infections | 2 | 2023 | 365 | 0.330 |
Why?
|
Quality of Health Care | 3 | 2021 | 4339 | 0.320 |
Why?
|
Africa South of the Sahara | 7 | 2021 | 751 | 0.320 |
Why?
|
Pyridones | 2 | 2024 | 818 | 0.320 |
Why?
|
Pandemics | 5 | 2023 | 8750 | 0.320 |
Why?
|
Tryptophan | 3 | 2017 | 482 | 0.320 |
Why?
|
Drug Resistance, Viral | 7 | 2021 | 869 | 0.310 |
Why?
|
Serologic Tests | 3 | 2019 | 383 | 0.310 |
Why?
|
Pregnancy, Unplanned | 2 | 2019 | 86 | 0.300 |
Why?
|
Ambulatory Care Facilities | 5 | 2024 | 940 | 0.300 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7458 | 0.290 |
Why?
|
Technology | 3 | 2022 | 296 | 0.280 |
Why?
|
Mental Health | 3 | 2021 | 3276 | 0.280 |
Why?
|
Biomedical Research | 1 | 2023 | 3464 | 0.280 |
Why?
|
Privacy | 3 | 2019 | 233 | 0.280 |
Why?
|
Life Style | 1 | 2019 | 3930 | 0.280 |
Why?
|
Antitubercular Agents | 4 | 2024 | 1391 | 0.270 |
Why?
|
Primary Prevention | 1 | 2014 | 1187 | 0.270 |
Why?
|
Benzoxazines | 2 | 2018 | 321 | 0.270 |
Why?
|
Rural Health | 5 | 2015 | 300 | 0.270 |
Why?
|
Inflammation | 4 | 2021 | 10863 | 0.260 |
Why?
|
Iran | 3 | 2024 | 762 | 0.260 |
Why?
|
Medical Informatics | 1 | 2013 | 739 | 0.260 |
Why?
|
Women | 2 | 2021 | 226 | 0.260 |
Why?
|
Health Personnel | 3 | 2022 | 3381 | 0.250 |
Why?
|
Fibrin Fibrinogen Degradation Products | 5 | 2019 | 425 | 0.250 |
Why?
|
Self Efficacy | 2 | 2023 | 643 | 0.240 |
Why?
|
Contraceptive Agents | 3 | 2022 | 147 | 0.240 |
Why?
|
Epidemics | 2 | 2022 | 517 | 0.240 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2024 | 295 | 0.240 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2013 | 939 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2023 | 10377 | 0.230 |
Why?
|
Smoking Cessation | 4 | 2020 | 2083 | 0.230 |
Why?
|
Diagnostic Tests, Routine | 2 | 2020 | 790 | 0.230 |
Why?
|
Clinical Competence | 1 | 2020 | 4847 | 0.230 |
Why?
|
Transportation | 3 | 2015 | 217 | 0.230 |
Why?
|
Biomedical Technology | 2 | 2017 | 210 | 0.230 |
Why?
|
Piperazines | 2 | 2024 | 2552 | 0.220 |
Why?
|
Postal Service | 2 | 2020 | 96 | 0.210 |
Why?
|
Hypertension | 2 | 2021 | 8615 | 0.210 |
Why?
|
Pain | 1 | 2017 | 5102 | 0.200 |
Why?
|
Data Collection | 2 | 2015 | 3324 | 0.200 |
Why?
|
Foot Bones | 1 | 2002 | 23 | 0.200 |
Why?
|
Chicago | 2 | 2020 | 255 | 0.200 |
Why?
|
Urban Population | 3 | 2020 | 2045 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2021 | 878 | 0.200 |
Why?
|
Behavioral Sciences | 1 | 2021 | 29 | 0.190 |
Why?
|
Reproductive Behavior | 1 | 2021 | 27 | 0.180 |
Why?
|
Child Behavior | 2 | 2019 | 865 | 0.180 |
Why?
|
Retrospective Studies | 12 | 2023 | 81768 | 0.180 |
Why?
|
Parents | 1 | 2015 | 3596 | 0.180 |
Why?
|
Men | 1 | 2021 | 65 | 0.180 |
Why?
|
Hematuria | 1 | 2002 | 233 | 0.180 |
Why?
|
Interpersonal Relations | 5 | 2017 | 1440 | 0.180 |
Why?
|
Geographic Information Systems | 2 | 2013 | 283 | 0.180 |
Why?
|
Contraception | 2 | 2022 | 362 | 0.180 |
Why?
|
Syphilis | 1 | 2023 | 243 | 0.180 |
Why?
|
Program Evaluation | 2 | 2021 | 2505 | 0.180 |
Why?
|
Clinical Trials as Topic | 4 | 2019 | 8051 | 0.170 |
Why?
|
HIV Integrase | 1 | 2021 | 122 | 0.170 |
Why?
|
Primary Health Care | 4 | 2020 | 4748 | 0.170 |
Why?
|
Interleukin-6 | 5 | 2021 | 3230 | 0.170 |
Why?
|
Hospitals | 3 | 2023 | 3905 | 0.170 |
Why?
|
Homosexuality | 1 | 2020 | 268 | 0.170 |
Why?
|
Attitude to Health | 3 | 2020 | 2025 | 0.170 |
Why?
|
Zambia | 3 | 2020 | 273 | 0.170 |
Why?
|
Trust | 3 | 2019 | 532 | 0.170 |
Why?
|
Managed Care Programs | 1 | 2005 | 942 | 0.170 |
Why?
|
Blood Chemical Analysis | 2 | 2018 | 436 | 0.170 |
Why?
|
Medically Uninsured | 1 | 2005 | 841 | 0.170 |
Why?
|
Time Factors | 13 | 2021 | 40267 | 0.160 |
Why?
|
Socioeconomic Factors | 7 | 2020 | 7861 | 0.160 |
Why?
|
Researcher-Subject Relations | 1 | 2018 | 15 | 0.160 |
Why?
|
Awards and Prizes | 1 | 2023 | 365 | 0.160 |
Why?
|
Culicidae | 1 | 2019 | 110 | 0.160 |
Why?
|
Stomach | 1 | 2003 | 703 | 0.160 |
Why?
|
Urban Health | 1 | 2021 | 535 | 0.160 |
Why?
|
DNA Fingerprinting | 1 | 2018 | 114 | 0.160 |
Why?
|
Treatment Outcome | 20 | 2024 | 65365 | 0.150 |
Why?
|
Adolescent Behavior | 2 | 2019 | 1190 | 0.150 |
Why?
|
Stillbirth | 1 | 2021 | 376 | 0.150 |
Why?
|
Pleasure | 1 | 2018 | 41 | 0.150 |
Why?
|
Regression Analysis | 8 | 2015 | 6350 | 0.150 |
Why?
|
Osteomyelitis | 1 | 2002 | 408 | 0.150 |
Why?
|
Maternal Mortality | 1 | 2021 | 307 | 0.150 |
Why?
|
Leishmania | 1 | 1998 | 75 | 0.150 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 2661 | 0.150 |
Why?
|
Odds Ratio | 7 | 2021 | 9681 | 0.150 |
Why?
|
World Health Organization | 3 | 2021 | 1327 | 0.140 |
Why?
|
Research Subjects | 1 | 2019 | 249 | 0.140 |
Why?
|
Dideoxynucleosides | 1 | 2017 | 135 | 0.140 |
Why?
|
Smoking | 5 | 2020 | 9109 | 0.140 |
Why?
|
Developed Countries | 2 | 2010 | 452 | 0.140 |
Why?
|
Public Health | 3 | 2021 | 2681 | 0.140 |
Why?
|
Treatment Failure | 5 | 2024 | 2664 | 0.140 |
Why?
|
Poverty | 3 | 2023 | 2721 | 0.140 |
Why?
|
Drug Therapy, Combination | 6 | 2016 | 6319 | 0.140 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 1998 | 137 | 0.140 |
Why?
|
Hospitalization | 4 | 2023 | 10844 | 0.140 |
Why?
|
Decision Support Techniques | 2 | 2018 | 2005 | 0.140 |
Why?
|
AIDS Serodiagnosis | 1 | 2018 | 220 | 0.130 |
Why?
|
Self Administration | 1 | 2017 | 388 | 0.130 |
Why?
|
Checklist | 2 | 2021 | 843 | 0.130 |
Why?
|
Violence | 2 | 2012 | 938 | 0.130 |
Why?
|
Child, Preschool | 8 | 2022 | 42654 | 0.130 |
Why?
|
Antigens, Protozoan | 1 | 1998 | 315 | 0.130 |
Why?
|
Social Isolation | 1 | 2019 | 369 | 0.130 |
Why?
|
United States | 9 | 2023 | 73144 | 0.130 |
Why?
|
Gender Identity | 1 | 2021 | 770 | 0.130 |
Why?
|
Midwifery | 1 | 2017 | 130 | 0.120 |
Why?
|
Sexual Abstinence | 1 | 2015 | 17 | 0.120 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4859 | 0.120 |
Why?
|
Patient Dropouts | 1 | 2017 | 411 | 0.120 |
Why?
|
Biometry | 1 | 2018 | 565 | 0.120 |
Why?
|
Public Health Practice | 1 | 2017 | 221 | 0.120 |
Why?
|
Health Resources | 2 | 2018 | 950 | 0.120 |
Why?
|
House Calls | 1 | 2017 | 171 | 0.120 |
Why?
|
National Health Programs | 2 | 2009 | 442 | 0.120 |
Why?
|
Diabetic Retinopathy | 1 | 2024 | 1299 | 0.120 |
Why?
|
Logistic Models | 5 | 2021 | 13323 | 0.120 |
Why?
|
Obstetric Labor Complications | 1 | 2017 | 243 | 0.120 |
Why?
|
Heart Rate, Fetal | 1 | 2015 | 76 | 0.120 |
Why?
|
Ischemia | 1 | 2003 | 1900 | 0.120 |
Why?
|
Saliva | 1 | 2019 | 854 | 0.120 |
Why?
|
Health Services Research | 2 | 2018 | 1817 | 0.110 |
Why?
|
Risk Factors | 16 | 2023 | 74954 | 0.110 |
Why?
|
Labor, Obstetric | 1 | 2017 | 323 | 0.110 |
Why?
|
Soil | 1 | 2014 | 118 | 0.110 |
Why?
|
Delivery, Obstetric | 1 | 2021 | 952 | 0.110 |
Why?
|
Helminthiasis | 1 | 2014 | 81 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2018 | 620 | 0.110 |
Why?
|
Dangerous Behavior | 1 | 2013 | 65 | 0.110 |
Why?
|
Interview, Psychological | 1 | 2016 | 812 | 0.110 |
Why?
|
Self Disclosure | 1 | 2014 | 249 | 0.110 |
Why?
|
Mental Disorders | 1 | 2013 | 6876 | 0.110 |
Why?
|
Markov Chains | 1 | 2016 | 977 | 0.110 |
Why?
|
Medicine, African Traditional | 1 | 2013 | 31 | 0.100 |
Why?
|
Recombination, Genetic | 1 | 2017 | 1526 | 0.100 |
Why?
|
Informed Consent | 1 | 2019 | 1010 | 0.100 |
Why?
|
Survival Analysis | 3 | 2020 | 10117 | 0.100 |
Why?
|
Drug Utilization | 1 | 2018 | 1191 | 0.100 |
Why?
|
HIV Antibodies | 1 | 2019 | 1341 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2015 | 20224 | 0.100 |
Why?
|
Boston | 2 | 2022 | 9371 | 0.100 |
Why?
|
Electrical Equipment and Supplies | 1 | 2012 | 28 | 0.100 |
Why?
|
San Francisco | 1 | 2012 | 166 | 0.100 |
Why?
|
Puerperal Disorders | 1 | 2014 | 303 | 0.100 |
Why?
|
Epitopes | 1 | 1998 | 2525 | 0.100 |
Why?
|
Medicaid | 1 | 2005 | 2842 | 0.100 |
Why?
|
Incidence | 9 | 2022 | 21544 | 0.100 |
Why?
|
Weight Loss | 1 | 2003 | 2715 | 0.100 |
Why?
|
Health Promotion | 2 | 2021 | 2209 | 0.100 |
Why?
|
Heterosexuality | 3 | 2021 | 309 | 0.090 |
Why?
|
Home Care Services | 1 | 2018 | 659 | 0.090 |
Why?
|
Risk | 2 | 2021 | 9635 | 0.090 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2017 | 622 | 0.090 |
Why?
|
Referral and Consultation | 2 | 2021 | 3627 | 0.090 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2010 | 39 | 0.090 |
Why?
|
Psychotherapy, Group | 1 | 2014 | 414 | 0.090 |
Why?
|
Obstetrics | 1 | 2017 | 676 | 0.090 |
Why?
|
Health Communication | 1 | 2013 | 216 | 0.090 |
Why?
|
Drug Implants | 2 | 2024 | 230 | 0.090 |
Why?
|
Models, Statistical | 3 | 2018 | 5099 | 0.080 |
Why?
|
Reimbursement Mechanisms | 1 | 2015 | 677 | 0.080 |
Why?
|
Metabolic Networks and Pathways | 1 | 2014 | 798 | 0.080 |
Why?
|
Risk-Taking | 4 | 2020 | 1026 | 0.080 |
Why?
|
Intention to Treat Analysis | 2 | 2022 | 417 | 0.080 |
Why?
|
Mass Vaccination | 1 | 2010 | 110 | 0.080 |
Why?
|
China | 6 | 2015 | 2389 | 0.080 |
Why?
|
Breast Feeding | 2 | 2020 | 1364 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2024 | 10776 | 0.080 |
Why?
|
Research Design | 3 | 2019 | 6209 | 0.080 |
Why?
|
Tobacco Use Disorder | 1 | 2014 | 708 | 0.080 |
Why?
|
Telephone | 1 | 2012 | 630 | 0.080 |
Why?
|
HIV Reverse Transcriptase | 2 | 2009 | 214 | 0.080 |
Why?
|
Health Policy | 1 | 2020 | 2698 | 0.070 |
Why?
|
Suicidal Ideation | 1 | 2018 | 1461 | 0.070 |
Why?
|
Forecasting | 1 | 2017 | 2948 | 0.070 |
Why?
|
Postnatal Care | 2 | 2020 | 273 | 0.070 |
Why?
|
Alkynes | 2 | 2018 | 327 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2728 | 0.070 |
Why?
|
Age Factors | 4 | 2019 | 18472 | 0.070 |
Why?
|
Cyclopropanes | 2 | 2018 | 437 | 0.070 |
Why?
|
Clinical Laboratory Techniques | 1 | 2012 | 749 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12092 | 0.070 |
Why?
|
Health Plan Implementation | 3 | 2020 | 338 | 0.070 |
Why?
|
Plasma | 2 | 2024 | 585 | 0.070 |
Why?
|
Genotype | 2 | 2018 | 13038 | 0.070 |
Why?
|
Abdominal Pain | 2 | 2003 | 1070 | 0.070 |
Why?
|
Reward | 1 | 2013 | 984 | 0.060 |
Why?
|
Malnutrition | 1 | 2012 | 631 | 0.060 |
Why?
|
Cross-Over Studies | 2 | 2024 | 2106 | 0.060 |
Why?
|
India | 2 | 2024 | 2324 | 0.060 |
Why?
|
Point-of-Care Systems | 2 | 2024 | 1238 | 0.060 |
Why?
|
Deoxyadenosines | 1 | 2024 | 27 | 0.060 |
Why?
|
Disease Progression | 2 | 2021 | 13646 | 0.060 |
Why?
|
Information Dissemination | 1 | 2013 | 1137 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2012 | 4637 | 0.060 |
Why?
|
Research | 1 | 2013 | 1981 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2016 | 12457 | 0.060 |
Why?
|
Papillomavirus Vaccines | 1 | 2010 | 497 | 0.060 |
Why?
|
Sampling Studies | 1 | 2005 | 616 | 0.060 |
Why?
|
Communication | 1 | 2018 | 3912 | 0.060 |
Why?
|
T-Lymphocytes | 2 | 2017 | 10266 | 0.050 |
Why?
|
Celiac Artery | 1 | 2003 | 65 | 0.050 |
Why?
|
Stomach Ulcer | 1 | 2003 | 120 | 0.050 |
Why?
|
Preconception Care | 1 | 2024 | 143 | 0.050 |
Why?
|
Aged | 10 | 2022 | 171544 | 0.050 |
Why?
|
Mesenteric Arteries | 1 | 2003 | 178 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 2020 | 1855 | 0.050 |
Why?
|
Fundus Oculi | 1 | 2024 | 560 | 0.050 |
Why?
|
Anorexia | 1 | 2003 | 152 | 0.050 |
Why?
|
Internship and Residency | 1 | 2023 | 5948 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2024 | 14736 | 0.050 |
Why?
|
Drug Combinations | 3 | 2013 | 2078 | 0.050 |
Why?
|
Latin America | 2 | 2015 | 416 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2016 | 4874 | 0.050 |
Why?
|
Leukocytosis | 1 | 2003 | 250 | 0.050 |
Why?
|
Radiography | 2 | 2003 | 6993 | 0.050 |
Why?
|
Models, Theoretical | 2 | 2024 | 3579 | 0.050 |
Why?
|
Africa, Northern | 1 | 2021 | 86 | 0.050 |
Why?
|
Cameroon | 1 | 2021 | 79 | 0.050 |
Why?
|
Gastritis | 1 | 2003 | 200 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2014 | 4411 | 0.050 |
Why?
|
Hematologic Tests | 1 | 2002 | 239 | 0.050 |
Why?
|
Probability | 2 | 2018 | 2482 | 0.050 |
Why?
|
Middle East | 1 | 2021 | 233 | 0.040 |
Why?
|
Polypharmacy | 1 | 2023 | 307 | 0.040 |
Why?
|
Artificial Intelligence | 1 | 2015 | 2661 | 0.040 |
Why?
|
Placebos | 2 | 2015 | 1668 | 0.040 |
Why?
|
Health Surveys | 3 | 2020 | 4056 | 0.040 |
Why?
|
Atherosclerosis | 1 | 2016 | 3431 | 0.040 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2003 | 281 | 0.040 |
Why?
|
Southeastern United States | 1 | 2019 | 93 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2024 | 1026 | 0.040 |
Why?
|
Nitriles | 1 | 2024 | 984 | 0.040 |
Why?
|
Isoniazid | 1 | 2020 | 288 | 0.040 |
Why?
|
New York City | 1 | 2021 | 737 | 0.040 |
Why?
|
Protozoan Vaccines | 1 | 1998 | 13 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 13082 | 0.040 |
Why?
|
Papillomavirus Infections | 1 | 2010 | 1640 | 0.040 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2010 | 2044 | 0.040 |
Why?
|
Vietnam | 1 | 2019 | 416 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2005 | 2437 | 0.040 |
Why?
|
Pulmonary Emphysema | 1 | 2003 | 690 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11914 | 0.040 |
Why?
|
Cities | 1 | 2020 | 543 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2003 | 13019 | 0.040 |
Why?
|
Lymphocyte Activation | 2 | 2018 | 5496 | 0.040 |
Why?
|
Communicable Disease Control | 1 | 2023 | 857 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2003 | 806 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5538 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1595 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 640 | 0.030 |
Why?
|
HLA-B Antigens | 1 | 2017 | 328 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1215 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 1155 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 12557 | 0.030 |
Why?
|
Hypotension | 1 | 2002 | 889 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2518 | 0.030 |
Why?
|
Quality of Life | 2 | 2015 | 13499 | 0.030 |
Why?
|
Prenatal Care | 2 | 2014 | 1159 | 0.030 |
Why?
|
Family Planning Services | 1 | 2018 | 279 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2114 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15455 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10656 | 0.030 |
Why?
|
Behavior Therapy | 1 | 2020 | 885 | 0.030 |
Why?
|
Schools | 1 | 2023 | 1496 | 0.030 |
Why?
|
Fever | 1 | 2002 | 1620 | 0.030 |
Why?
|
Vulnerable Populations | 1 | 2020 | 718 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1722 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15939 | 0.030 |
Why?
|
Infant, Newborn | 3 | 2023 | 26410 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2018 | 943 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2022 | 22292 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2017 | 664 | 0.030 |
Why?
|
Risk Assessment | 3 | 2021 | 24316 | 0.030 |
Why?
|
Contraceptive Agents, Female | 1 | 2015 | 123 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1555 | 0.030 |
Why?
|
Genome, Viral | 1 | 2017 | 673 | 0.030 |
Why?
|
Retina | 1 | 2024 | 2661 | 0.030 |
Why?
|
Comorbidity | 2 | 2021 | 10588 | 0.030 |
Why?
|
Fertility | 1 | 2018 | 772 | 0.030 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2014 | 117 | 0.030 |
Why?
|
Prognosis | 3 | 2019 | 30020 | 0.030 |
Why?
|
Dyspnea | 1 | 2021 | 1351 | 0.030 |
Why?
|
Internal-External Control | 1 | 2014 | 350 | 0.030 |
Why?
|
Databases, Factual | 2 | 2024 | 8072 | 0.030 |
Why?
|
Argentina | 1 | 2013 | 249 | 0.030 |
Why?
|
Models, Psychological | 1 | 2016 | 828 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 15652 | 0.030 |
Why?
|
Organophosphorus Compounds | 1 | 2013 | 207 | 0.020 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2012 | 62 | 0.020 |
Why?
|
Infant | 3 | 2023 | 36512 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2021 | 1544 | 0.020 |
Why?
|
Triage | 1 | 2019 | 994 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 1004 | 0.020 |
Why?
|
Social Behavior | 1 | 2018 | 1146 | 0.020 |
Why?
|
Body Weight | 2 | 2016 | 4630 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2023 | 2961 | 0.020 |
Why?
|
Cytokines | 2 | 2015 | 7443 | 0.020 |
Why?
|
ROC Curve | 1 | 2019 | 3622 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39405 | 0.020 |
Why?
|
Ethics, Research | 1 | 2013 | 177 | 0.020 |
Why?
|
Stereotyping | 1 | 2013 | 242 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2019 | 2353 | 0.020 |
Why?
|
Perception | 1 | 2017 | 1206 | 0.020 |
Why?
|
Spouse Abuse | 1 | 2012 | 182 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2337 | 0.020 |
Why?
|
Creatinine | 1 | 2016 | 1915 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2727 | 0.020 |
Why?
|
Animals | 2 | 2019 | 169322 | 0.020 |
Why?
|
Biopsy | 1 | 2002 | 6808 | 0.020 |
Why?
|
Mutation | 4 | 2021 | 30230 | 0.020 |
Why?
|
Peru | 1 | 2013 | 890 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2002 | 2171 | 0.020 |
Why?
|
Brazil | 1 | 2013 | 1247 | 0.020 |
Why?
|
California | 1 | 2012 | 1443 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1255 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 954 | 0.020 |
Why?
|
Local Government | 1 | 2007 | 83 | 0.020 |
Why?
|
Travel | 1 | 2013 | 800 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 2027 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 712 | 0.020 |
Why?
|
Health Literacy | 1 | 2012 | 468 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4774 | 0.020 |
Why?
|
Plasma Exchange | 1 | 2007 | 160 | 0.020 |
Why?
|
Algorithms | 2 | 2023 | 14154 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 7074 | 0.020 |
Why?
|
Oximetry | 1 | 1989 | 462 | 0.020 |
Why?
|
Government Programs | 1 | 2007 | 278 | 0.020 |
Why?
|
Social Class | 1 | 2014 | 2008 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2017 | 3666 | 0.020 |
Why?
|
Expert Systems | 1 | 2005 | 79 | 0.020 |
Why?
|
Antigens, CD | 1 | 2015 | 4031 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4647 | 0.010 |
Why?
|
Financing, Government | 1 | 2007 | 473 | 0.010 |
Why?
|
Nutritional Status | 1 | 2012 | 1627 | 0.010 |
Why?
|
Health Education | 1 | 2010 | 1057 | 0.010 |
Why?
|
Health Care Costs | 1 | 2017 | 3267 | 0.010 |
Why?
|
Lung | 1 | 2002 | 10087 | 0.010 |
Why?
|
Decision Trees | 1 | 2005 | 509 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5890 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6541 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2013 | 2784 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2007 | 1309 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2012 | 3064 | 0.010 |
Why?
|
Drug Costs | 1 | 2007 | 1196 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3267 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 16027 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2007 | 6238 | 0.010 |
Why?
|
Disease Outbreaks | 1 | 2007 | 1762 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 13050 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2018 | 59683 | 0.010 |
Why?
|
Phenotype | 1 | 2005 | 16716 | 0.000 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1629 | 0.000 |
Why?
|